Rezolute to Present Phase 3 Data at Endocrine Society Meeting Despite Prior Failure
Event summary
- Rezolute will present four data sets at the Endocrine Society's annual meeting June 13-16, 2026, including Phase 3 sunRIZE study results.
- The Phase 3 sunRIZE study failed to meet primary endpoints in December 2025 but showed some glycemic improvements.
- Presentations include an oral session on congenital hyperinsulinism and three posters on natural history, adverse outcomes, and compassionate use cases.
- Ersodetug is a monoclonal antibody targeting refractory hypoglycemia from congenital or acquired hyperinsulinism.
The big picture
Rezolute's presentations come after its Phase 3 study failed to meet primary endpoints, raising questions about ersodetug's regulatory future. The company is focusing on secondary endpoints and FDA engagement to potentially salvage the program. This reflects broader challenges in developing treatments for ultra-rare diseases where small patient populations complicate trial design and outcome interpretation.
What we're watching
- Regulatory Pathway
- Whether FDA's independent evaluation of sunRIZE data will open a path forward for ersodetug approval.
- Clinical Efficacy
- How the nominally significant glycemic improvements observed in sunRIZE will be interpreted by clinicians.
- Commercial Potential
- The pace at which Rezolute can advance ersodetug for tumor-induced hypoglycemia given the compassionate use data.